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Objective—The cyclin-dependent kinase (CDK) inhibitor flavopiridol is currently being tested in clinical trials as
anticancer drug. Beyond its cell death–inducing action, we hypothesized that flavopiridol affects inflammatory
processes. Therefore, we elucidated the action of flavopiridol on leukocyte–endothelial cell interaction and endothelial
activation in vivo and in vitro and studied the underlying molecular mechanisms.
Methods and Results—Flavopiridol suppressed concanavalin A–induced hepatitis and neutrophil infiltration into liver
tissue. Flavopiridol also inhibited tumor necrosis factor-–induced leukocyte–endothelial cell interaction in the mouse
cremaster muscle. Endothelial cells were found to be the major target of flavopiridol, which blocked the expression of
endothelial cell adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and
E-selectin), as well as NF-B-dependent transcription. Flavopiridol did not affect inhibitor of B (IB) kinase, the
degradation and phosphorylation of IB, nuclear translocation of p65, or nuclear factor-B (NF-B) DNA-binding
activity. By performing a cellular kinome array and a kinase activity panel, we found LIM domain kinase-1 (LIMK1),
casein kinase 2, c-Jun N-terminal kinase (JNK), protein kinase C (PKC), CDK4, CDK6, CDK8, and CDK9 to be
influenced by flavopiridol. Using specific inhibitors, as well as RNA interference (RNAi), we revealed that only CDK9
is responsible for the action of flavopiridol.
Conclusion—Our study highlights flavopiridol as a promising antiinflammatory compound and inhibition of CDK9 as a novel
approach for the treatment of inflammation-associated diseases. (Arterioscler Thromb Vasc Biol. 2011;31:280-288.)
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Flavopiridol (alvocidib) is a synthetic flavone structurallyrelated to an alkaloid purified from Dysoxylum binec-
tariferum, a plant used in Indian folk medicine.1 Flavopiridol
was found to exert cytotoxic effects, which were ascribed to
the inhibition of cyclin-dependent kinases (CDKs), ie, the
blockade of cell cycle progression.1 CDKs represent crucial
regulators of the cell cycle. An overactivity of cell cycle
CDKs can be observed in tumor cells, leading to their growth
advantage. Consequently, CDK inhibition has been proposed
as novel anticancer strategy. Flavopiridol was reported to
possess potent antiproliferative action on 60 human cancer
cell lines in the US National Cancer Institute screen panel1
and was the first CDK inhibitor to undergo clinical trials.
Currently, flavopiridol is evaluated in numerous studies for
treating hematologic and solid cancers.
Based on the cell growth-inhibiting feature of flavopiridol,
the compound was tested for its effect on the overgrowth of
synovial fibroblasts in collagen-induced murine arthritis and
was found to suppress synovial hyperplasia.2 Moreover, CDK
inhibitors were suggested to induce immune cell death and,
thus, to enhance the resolution of inflammation.3 Surpris-
ingly, beyond the antiproliferative and cell death–inducing
way of action, no studies have as yet focused on the action of
flavopiridol, and CDK inhibitors in general, on an early and
crucial step in inflammation, the interaction of leukocytes
with endothelial cells (ECs). An excessive leukocyte extrav-
asation from the blood into the tissue—a process that is
tightly regulated by the endothelium—is a hallmark of
inflammation and contributes to the pathogenesis and pro-
gression of many severe inflammation-associated patholo-
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gies, such as atherosclerosis, arthritis, or asthma. We hypoth-
esized that flavopiridol exerts antiinflammatory actions by
inhibition of leukocyte infiltration via a direct influence on
endothelial activation. Therefore, we tested the antiinflam-
matory and leukocyte extravasation-inhibiting effect of
flavopiridol in different in vivo models and, moreover,
investigated the underlying molecular mechanisms of this
action with a special focus on the signaling processes in
inflammation-activated ECs.
Methods
Materials
The CDK4/6 inhibitor fascaplysin (2,13-dihydro-13-oxopyrido[1,2-
a:3,4-b]diindol-5-IMchloride) was from Sigma-Aldrich
(Taufkirchen, Germany), the c-Jun N-terminal kinase inhibitor
SP600125 (1,9-pyrazoloanthrone) was from Enzo Life Sciences (Lo¨r-
rach, Germany), and the casein kinase 2 (CK2) inhibitor 4,5,6,7-
tetrabromo-2-azabenzimidazole was from Tocris (Bristol, UK). The
CK2 inhibitor quinalizarin (1,2,5,8-tetrahydroxyanthracene-9,10-dione)
was a kind gift of Prof Lorenzo Pinna (University of Padua, Padua,
Italy). The myristoylated PKC pseudosubstrate inhibitor (Myr-
LHQRRGAIKQAKVHHVKC-NH2) was from Calbiochem
(Darmstadt, Germany).
Concanavalin A–Induced Murine Hepatitis
Male mice (C57BL/6, 6 to 8 weeks; animal facilities of the
University Medical Center Hamburg-Eppendorf) received human
care according to the guidelines of the US National Institutes of
Health, as well as the German governmental requirements. The
model has been described previously in detail.4 Briefly, concanavalin
A (ConA; Sigma-Aldrich) was administered to mice intravenously at
15 mg/kg. Flavopiridol (44 ng) was administered intravenously 15
minutes before ConA. Mice were euthanized 8 hours after ConA
application. Plasma enzyme activity of alanine aminotransferase and
aspartate aminotransferase were assessed using an automated proce-
dure with COBAS MIRA (Roche, Basel, Switzerland). Liver tissue
paraffin sections were stained with hematoxylin and eosin and a
naphthol-AS-D-chloroacetate-esterase kit (Sigma-Aldrich). In addi-
tion, myeloperoxidase (MPO) activity of liver tissue homogenates
was determined photometrically (450 nm) with dianisidine as a
substrate.
Intravital Microscopy and Cremaster
Muscle Preparation
Experiments with male mice (C57BL/6, 6 to 8 weeks; Charles River,
Sulzfeld, Germany) were performed in accordance with the local
animal protection legislation (Government of Upper Bavaria). Sur-
gical preparation of cremaster muscles and intravital microscopy
were performed as described previously.5
Cell Culture
Primary human umbilical vein endothelial cells (HUVECs) were
isolated and cultured as described previously.6 The human micro-
vascular EC line CDC/EU.HMEC-1 was kindly provided by the
Centers for Disease Control and Prevention (Atlanta, Ga).7 Human
neutrophil granulocytes were separated from heparinized peripheral
blood of healthy volunteers by using CD15 MicroBeads (Miltenyi,
Bergisch Gladbach, Germany).
Neutrophil Adhesion Assay
Neutrophils were added to a HUVEC monolayer and allowed to
adhere for 30 minutes. Adhered neutrophils were quantified by an
MPO assay.
Flow Cytometric Analysis
Neutrophils were primed with 1 mol/L dihydrorhodamine-123
(Invitrogen, Karlsruhe, Germany) for 10 minutes, treated as indi-
cated, and analyzed by flow cytometry (FACSCalibur, Becton
Dickinson). HUVECs were treated as indicated, trypsinized, forma-
lin fixed, incubated with the respective antibodies, and analyzed by
flow cytometry (FACSCalibur).
Quantification of Apoptosis and Cell Viability
Quantification of apoptosis in HUVECs was carried out as described
by Nicoletti et al.8 HUVEC viability was measured by the CellTiter-
Blue assay (Promega, Mannheim, Germany).
Western Blot Analysis
Western blot analysis was performed as described previously.9
Densitometric analysis on normalization (loading control) was per-
formed with ImageJ, version 1.43u (National Institutes of Health).
Dual Luciferase Reporter Assay
Firefly luciferase reporter vector pGL4.32[luc2P/nuclear factor
(NF)-B-RE/Hygro] and Renilla luciferase reporter vector pGL4.74
[hRluc/TK] were from Promega. HUVECs were transfected using the
Amaxa HUVEC Nucleofactor kit (Lonza, Cologne, Germany).
Luciferase activity was determined using the Dual Luciferase Re-
porter Assay system (Promega).
In Vitro IKK Kinase Activity Assay
The effect of flavopiridol on purified IKB kinase  (IKK) activity
was determined using the HTScan IKK Kinase Assay Kit (Cell
Signaling).
NF-B p65 Translocation and NF-B
DNA-Binding Activity
Immunocytochemistry and electrophorectic mobility shift assay were
performed as described previously.6 Densitometric analysis was per-
formed with ImageJ version 1.43u (National Institutes of Health).
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total mRNA from HUVECs, liver tissue, and cremaster muscle
tissue was isolated (RNeasy Mini or Fibrous Tissue Kit; Qiagen,
Hilden, Germany). Quantitative reverse transcription–polymerase
chain reaction was performed as described previously.6
Gene Silencing
Transfection of HUVECs was performed with the Amaxa HUVEC
Nucleofactor kit (Lonza). On target plus short interfering RNA
(siRNA) from Dharmacon (Lafayette, Colo) was used. In addition,
HUVECs treated with infectious adenoviruses encoding short hairpin
RNA (shRNA; nontargeting shRNA or CDK9 shRNA) were pur-
chased from Sirion (Martinsried, Germany).
Kinome Chip Analysis (PepChip)
The PepChip kinome array was performed by Pepscan Presto BV
(Lelystad, the Netherlands) as described previously.10 Briefly,
HUVECs were treated either with tumor necrosis factor- (TNF-;
10 ng/mL) for 15 minutes or with flavopiridol (100 nmol/L) for 30
minutes before TNF-. Native protein lysates were generated by the
M-PER buffer (Pierce, Rockford, Ill). Aliquots of the lysates were
mixed with activation solution containing 20 Ci of [-33P]ATP.
Supernatants of this mixture were loaded onto the chip and incubated
for 2 hours at 37°C. On the chip, 1152 different peptides with
specific phosphorylation motifs for the respective kinase are spotted
in triplicate. Phosphor-storage screens were exposed to the chip.
In Vitro Kinase Panel
A radiometric protein kinase assay (33PanQinase Activity Assay,
ProQinase, Freiburg, Germany) was used for measuring the kinase
activity of 255 protein kinases as described previously.11 Briefly, the
kinase assays were performed in 96-well FlashPlates (Perkin-Elmer,
Boston, Mass). The reaction cocktail contained nonradioactive and
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[-33P]ATP, the test sample (in 10% dimethyl sulfoxide), and a
kinase/substrate mixture. Flavopiridol was tested at 9 concentrations
in the range of 105 to 109 mol/L at a final dimethyl sulfoxide
concentration of 1%.
Statistical Analysis
GraphPad Prism, version 3.03, was used. An unpaired t test was
performed to compare 2 groups. For 3 or more groups, 1-way analysis
of variance (ANOVA) followed by the Newman-Keuls post hoc test
was used. Data from the cremaster model were analyzed with the
Mann-Whitney rank sum test. Data are expressed as meanSEM.
Results
Flavopiridol Reduces Inflammation in
ConA-Induced Liver Injury
In mice, hepatitis was induced by intravenous application of
ConA (15 m/kg). The liver injury was greatly suppressed by
pretreatment (15 minutes) with flavopiridol (44 ng, IV), as
proven by a large decrease in the serum levels of alanine
transaminase and aspartate transaminase (Figure 1A). This
protective effect of flavopiridol was further confirmed by
microscopic examinations of liver sections (hematoxylin and
eosin staining) showing that flavopiridol lowered ConA-
triggered necrosis (Figure 1B). Neutrophils are the key initiators
of the subsequent lymphocyte recruitment and liver injury
caused by ConA. Flavopiridol strongly inhibited neutrophil
infiltration of the liver, as shown in the histological images in
Figure 1C. A quantification of the neutrophil count is given in
Figure 1D. Moreover, the activity of MPO, a marker for
neutrophil infiltration, was dramatically decreased by flavopiri-
dol in liver tissue (Figure 1E). In addition, we detected a
significant decrease of the endothelium-specific adhesion mole-
cule E-selectin (Figure 1F, left) and of the intercellular adhesion
molecule-1 (ICAM-1) mRNA expression in flavopiridol-treated
mice (Figure 1F, right). These data show that the antiinflamma-
tory action of flavopiridol is associated with the reduction of
leukocyte infiltration and cell adhesion molecule expression.
Flavopiridol Abrogates Leukocyte Transmigration
and Adhesion in TNF--Activated Venules of the
Mouse Cremaster Muscle
Intravital microscopy of the mouse cremaster muscle showed
that the number of leukocytes that migrated through the
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Figure 1. Flavopiridol protects
against ConA-induced liver
injury. Mice were treated IV
with 15 mg/kg ConA. Flavopiri-
dol (FP, 44 ng, IV) was admin-
istered 15 minutes before
ConA. Liver tissues were
removed 8 hours after ConA
administration. n6 per group.
A, Plasma levels of aspartate
transaminase (AST) and ala-
nine transaminase (ALT) were
assessed. B, Representative
hematoxylin/eosin–stained
sections of livers. Scale bar
represents 50 m. Arrows indi-
cate necrotic area. Bar graph:
The percentage of liver paren-
chyma with necrotic injury was
assessed per high power field
(HPF). C, Representative
image of liver sections stained
for naphthol-AS-D-chloroacetate
esterase. Arrows indicate neutro-
phils. Bar represents 100 m. D,
Neutrophil count per HPF. E,
MPO activity in the liver tissue. F,
E-selectin and ICAM-1 mRNA
expression in the liver tissue.
Data are expressed as ICAM-1/
GAPDH and E-selectin/GAPDH
ratios. *P0.05 versus ConA.
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endothelium (transmigration) on intrascrotal injection of
TNF- (300 ng) was significantly decreased in the group
concurrently treated with flavopiridol (11 ng, IV) (Figure 2A,
left). Leukocyte adherence to the endothelium was also
reduced (Figure 2A, right). Flavopiridol did not affect hemo-
dynamic parameters, such as the vessel diameter, centerline
blood flow velocity, and wall shear rate (Supplemental Table
I, available online at http://atvb.ahajournals.org). Also, the
systemic white blood cell count was not altered by flavopiri-
dol, suggesting that no pronounced cytotoxic effect (eg,
apoptosis induction) occurred on leukocytes. Furthermore,
we assessed the motility of interstitially migrating leukocytes
in detail (Supplemental Table II), indicating that flavopiridol
did also not affect this important parameter of leukocyte
activation. We conclude that leukocytes might not be the
primary target of flavopiridol. In analogy to the liver injury
model, we also analyzed ICAM-1 and observed a significant
decrease of ICAM-1 mRNA expression in flavopiridol-
treated cremaster muscle tissue (Figure 2B).
Flavopiridol Reduces TNF--Induced Adhesion of
Neutrophils to HUVECs
To proceed with mechanistic analyses, we first confirmed that
leukocyte-EC interaction is also impaired in vitro. In fact, the
adhesion of formyl-methionyl-leucyl-phenylalanine-activated
neutrophils onto a TNF--activated EC monolayer was re-
duced when (only) ECs were treated with flavopiridol (Figure
2C). The number of adhered leukocytes did not change when
neutrophils were also treated with flavopiridol. Furthermore,
we checked the influence of flavopiridol on the respiratory
burst, an important marker of neutrophil activation, and found
that the formyl-methionyl-leucyl-phenylalanine-induced pro-
duction of reactive oxygen species was not altered in the
presence of flavopiridol, even at high concentrations (Figure
2D). These data indicate that neutrophils are not the major
target of flavopiridol.
Flavopiridol Strongly Reduces the Expression of
Endothelial CAMs
Treatment of ECs with flavopiridol concentration-dependently
inhibited the TNF--evoked total (Figure 3A), as well as cell
surface levels of the EC adhesion molecules ICAM-1 (IC50: 27
nmol/L), vascular cell adhesion molecule-1 (VCAM-1; IC50, 74
nmol/L), and E-selectin (IC50: 118 nmol/L) (Figure 3B). As
shown in Figure 3C, flavopiridol effectively inhibited the TNF-
-induced ICAM-1 mRNA expression, suggesting that fla-
vopiridol might interfere with transcriptional processes. Under
basal conditions, flavopiridol (alone) did not affect ICAM-1
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Figure 2. Flavopiridol attenuates TNF--
evoked leukocyte-EC interaction in vivo
and in vitro but does not influence neu-
trophil activation. A and B, Mice were
treated IV with flavopiridol (FP, 11 ng).
Concurrently, TNF- (300 ng) was
applied by intrascrotal injection. Cremas-
ter muscle venules were observed 4
hours after injection of TNF-. n3 per
group. A, The number of transmigrated
and adherent leukocytes was quantified
in cremaster venules using intravital
microscopy. *P0.05 versus TNF-. B,
ICAM-1 mRNA expression in cremaster
muscle tissue was analyzed. Data are
expressed as the ICAM-1/GAPDH ratio.
*P0.05 versus TNF-. C, Human neu-
trophils were either left untreated or
treated with FP (100 nmol/L) for 30 min-
utes. HUVECs were treated with TNF-
(10 ng/mL) for 24 hours and pretreated
with FP (100 nmol/L) for 30 minutes.
Neutrophils were allowed to adhere to
the HUVEC monolayer for 30 minutes.
The number of adherent neutrophils was
quantified by measuring MPO activity.
n3. *P0.05 compared with TNF--ac-
tivated HUVECs coincubated with
untreated neutrophils; #P0.05 com-
pared with TNF--activated HUVECs
coincubated with FP-treated neutrophils.
D, Human neutrophils were either left
untreated (Co) or treated with formyl-
methionyl-leucyl-phenylalanine (fMLP)
(100 nmol/L, 15 minutes) in the presence
or absence of FP (30-minute pretreat-
ment). Neutrophil activation was
assessed by measuring oxidative burst–
triggered dihydrorhodamine (DHR) oxida-
tion via flow cytometry. n3.
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mRNA expression (Figure 3C). To exclude the possibility that
the observed effects on ECs are simply due to cytotoxicity, we
measured the apoptotic cell rate, as well as the metabolic cell
viability and observed that flavopiridol had no significant effect
on both parameters up to a concentration of 100 nmol/L (Figure
3D). Moreover, to exclude effects due to EC heterogeneity, the
results regarding the influence of flavopiridol on cell adhesion
molecule expression, apoptosis, and cell viability obtained in
macrovascular HUVECs were confirmed in human microvascu-
lar endothelial cells as shown in Supplemental Figure I.
Flavopiridol Inhibits NF-B Consensus Promoter
Activity but Does Not Influence the Activation
Cascade of NF-B
As shown in Figure 4A, flavopiridol concentration-
dependently suppressed TNF--triggered NF-B consensus
promotor activity, as assessed by a dual luciferase reporter
gene assay. We analyzed the activation cascade of NF-B and
observed no effect of flavopiridol on recombinant human
IKK kinase (Figure 4B) or on the phosphorylation of
IKK/ in ECs (Figure 4C). Flavopiridol did not prevent the
degradation of the NF-B inhibitor IB- (Figure 4D) and
did not affect the TNF--induced phosphorylation of the
NF-B p65 subunit (Figure 4E). Neither the TNF--triggered
nuclear translocation of p65 (as assessed microscopically;
Figure 4F and Supplemental Figure II) nor the NF-B
DNA-binding activity (Figure 4G) was altered by flavopiri-
dol. These findings suggest that flavopiridol is able to impair
NF-B consensus promotor activity but does not interfere
with the canonical activation cascade of this proinflammatory
transcription factor.
The Inhibition of the Activity of Several
TNF--Induced Kinases Is Not Responsible for the
Actions of Flavopiridol
We performed a cellular kinome array (PepChip) to get
insights into the kinases that are (directly or indirectly)
influenced by flavopiridol. ECs were treated either with
TNF- alone or with both flavopiridol and TNF-. The
kinases with the highest rate of inhibition by flavopiridol
are stated in the supplemental materials (Table 3). As a
next step, we sought to answer the question whether the
inhibition of these kinases is the cause for the observed
effects of flavopiridol. The reduction of ICAM-1 expres-
sion served as readout parameter. The silencing of LIMK1
via siRNA did not affect the ability of TNF- to induce
ICAM-1 (Figure 5A), nor did the inhibitor of c-Jun
N-terminal kinase (Figure 5B), the inhibitors of CK2
(Figure 5C), or the PKC blocker (Figure 5D). Thus, we
conclude that the inhibition of these kinases by flavopiri-
dol is not linked to the ICAM-1 reduction.
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Figure 3. Flavopiridol reduces
TNF--induced endothelial adhe-
sion molecule expression without
exhibiting cytotoxic effects. A and
B, HUVECs were either left
untreated (Co) or treated with
TNF- (10 ng/mL, 24 hours for
ICAM-1 and VCAM-1, 6 hours for
E-selectin). Flavopiridol (FP) was
applied 30 minutes before TNF-.
A, ICAM-1 and VCAM-1 total
protein expressions were ana-
lyzed by Western blotting fol-
lowed by densitometric analysis.
n3. *P0.05 versus TNF-. B,
ICAM-1, E-selectin, and VCAM-1
surface expressions were
assessed by flow cytometry.
n3. *P0.05 versus TNF-. C,
HUVECs were either left
untreated (Co) or treated with
TNF- (10 ng/mL, 4 hours). FP
was applied for 30 minutes alone
or before TNF-. ICAM-1 mRNA
expression was determined via
quantitative reverse transcription–
polymerase chain reaction. n3.
*P0.05 versus TNF-. D,
HUVECs were treated for 24 and
48 hours with FP. The apoptotic
cell rate (subdiploid DNA content)
was analyzed by flow cytometry
on staining of permeabilized cells
with propidium iodide. Cell viabil-
ity of HUVECs treated for 24 and
48 hours with FP was determined
by measuring their metabolic
activity using the CellTiter-Blue
assay. n3. *P0.05 versus
untreated cells.
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Inhibition of CDK9 by Flavopiridol Is Responsible
for Its Effects
Because the kinome array did not entirely cover CDKs, we
additionally determined the IC50 profile of flavopiridol in a
33PanQinase in vitro kinase activity assay (comprising 255
kinases) and revealed that flavopiridol in concentrations
lower than 100 nmol/L exclusively targets CDK4, CDK6,
CDK8, CDK9, and LIMK1 (Supplemental Table IV). Con-
sequently, we used a CDK4/6 inhibitor and silenced CDK8
and CDK9 to figure out their role in ICAM-1 reduction. We
found that CDK4 and CDK6 are not involved in the effect of
flavopiridol (Figure 6A) and that CDK8-silenced ECs show a
greatly increased ICAM-1 expression in response to TNF-
(Figure 6B). Most importantly, in the absence of CDK9, the
expressions of ICAM-1 (Figure 6C), VCAM-1 (Figure 6D),
and E-selectin (Figure 6E) were significantly inhibited, sug-
gesting that CDK9 is crucially involved in the effect of
flavopiridol.
Discussion
Besides their role as promising antitumor therapeutics, CDK-
inhibiting drugs have been proposed as novel antiinflamma-
tory agents by their properties to increase apoptosis of
neutrophil granulocytes and to inhibit lymphocyte prolifera-
tion.12,13 Nevertheless, investigations regarding an antiinflam-
matory potential of flavopiridol are rare. In the context of
Figure 4. Flavopiridol inhibits
TNF--induced NF-B con-
sensus promotor activity but
does not affect the canonical
NF-B activation cascade. A,
HUVECs were cotransfected
with an NF-B firefly lucif-
erase reporter gene vector
and a Renilla luciferase con-
trol vector. Twenty-four hours
after transfection, HUVECs
were either left untreated (Co)
or treated with TNF- (10
ng/mL) for 5.5 hours. Fla-
vopiridol (FP) was applied 30
minutes before TNF-. A Dual
Luciferase Reporter assay
was used to assess NF-B-
dependent reporter gene
expression, which is
expressed as ratio activity
firefly luciferase/Renilla lucif-
erase. n3. *P0.05 versus
TNF-. B, The influence of FP
on recombinant active IKK
kinase was measured by a
HTScan IKK kinase activity
assay. The pankinase
inhibitor staurosporine (St,
100 mol/L) was used as
positive control. n3.
*P0.05 versus TNF-. C to
G, HUVECs were either left
untreated or treated with
TNF- (10 ng/mL). FP (100
nmol/L) was applied 30 min-
utes before TNF-. C to E,
HUVEC lysates were analyzed
for the protein levels of
phospho-IKK/, IB-,
phospho(Ser536)-p65, and
-actin via Western blotting
followed by densitometric
analysis. For a proper detec-
tion of phospho-IKK/, cells
were pretreated for 30 min-
utes with the protein phos-
phatase inhibitor calyculin
(100 nmol/L). n3. *P0.05
versus untreated cells;
#P0.05; n.s., not signifi-
cantly different. F, Immunocy-
tochemistry and confocal
microscopy were performed
to determine p65 transloca-
tion into the nucleus. The
median nuclear fluorescence intensity was analyzed. n3. *P0.05 versus untreated cells. G, Nucleic extracts were prepared
from HUVEC lysates and subsequently analyzed for their NF-B DNA-binding activity via radioactive gel shift assay followed by
densitometric analysis. *P0.05 versus untreated cells; #P0.05; n.s., not significantly different.
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hepatic acute phase response, 1 study showed that the
interleukin (IL)-6/STAT3 signaling was disrupted by fla-
vopiridol in hepatoblastoma cells.14 Moreover, flavopiridol
was found to attenuate the proliferation of synovial fibro-
blasts in vitro and to inhibit synovial hyperplasia in a murine
model of arthritis without suppressing lymphocyte function.2
In our present work, we provide for the first time evidence
that flavopiridol works as an antiinflammatory agent indepen-
dent of affecting proliferative and cell death–inducing actions. It
effectively blocked leukocyte infiltration and leukocyte-EC in-
teraction by hampering endothelial activation, a crucial event in
the onset and maintaining of inflammation.
In the model of ConA-induced murine hepatitis, flavopiri-
dol effectively blocked neutrophil infiltration of the liver and
reduced ICAM-1 and E-selectin expression. It was recently
demonstrated that neutrophil recruitment in the liver sinu-
soids does not primarily depend on these classic adhesion
molecules but on the interaction of CD44 and hyaluronan.15 A
novel set of experiments is required to analyze whether
flavopiridol affects the CD44-hyaluronan system; however, it
can be speculated that flavopiridol might influence both the
CD44-hyaluronan and the ICAM-1/E-selectin pathway of
leukocyte recruitment.
An important finding of this work is the fact that flavopiri-
dol effectively blocks NF-B-dependent gene expression
(luciferase reporter gene, ICAM-1 expression), but not by
affecting the canonical NF-B activation cascade (IKK acti-
vation, IB degradation, nuclear p65 translocation, NF-B
DNA-binding). Supporting our data, an inhibitory effect of
flavopiridol on NF-B-dependent reporter gene and ICAM-1
expression was also described in studies evaluating the action
of flavopiridol on TNF--induced genes in A293 (human
kidney) and HL60 (human myeloid leukemia) cells, respec-
tively.16,17 However, in contrast to our study, flavopiridol was
reported to suppress NF-B signaling by inhibition of IKK
activation, IB degradation, p65 phosphorylation and trans-
location, as well as NF-B DNA-binding activity in different
cancer cell lines.16 This striking discrepancy cannot be easily
explained. We assume that it might be based on a strong cell
type–dependent action of flavopiridol.
We found that instead of affecting the canonical NF-B
activation cascade, flavopiridol exerted its action on ICAM-1
expression via inhibition of CDK9. Interestingly, although
high (mol/L) concentrations of flavopiridol are able to
inhibit a wide variety of cellular kinases,18 at concentrations
as low as the IC50 values of adhesion molecule reduction (27
nmol/L for ICAM-1), it exerts an inhibitory function on only
5 kinases. This suggests that the antiinflammatory action of
flavopiridol is not based on a broad-spectrum kinase inhibi-
tion but on a rather selective interference by targeting CDK9.
CDK9 is crucially involved in the control of gene tran-
scription. The positive transcriptional elongation factor b
(P-TEFb), which regulates the elongation phase of RNA
polymerase II–dependent transcription, is a heterodimer com-
posed of CDK9 and cyclin T1. P-TEFb acts by phosphory-
lation of negative elongation factors, as well as of RNA
polymerase II. From cDNA microarray analyses, it is known
that flavopiridol suppresses transcription in a concentration-
dependent manner: 60 nmol/L does not affect cellular gene
expression, whereas 300 nmol/L decreases mRNA levels.19
Applying nuclear run-on assays, Chao and Price revealed that
flavopiridol did not influence transcription at 10, 30, and 100
Figure 5. LIMK1, c-Jun N-terminal
kinase, CK2, and PKC do not mediate
the effect of flavopiridol on ICAM-1
expression. A to D, HUVECs were either
left untreated (Co) or treated with TNF-
(10 ng/mL) for 24 hours. ICAM-1 surface
expression were assessed by flow
cytometry. A, Cells were transfected with
LIMK1 siRNA or nontargeting (nt) siRNA
24 hours before TNF- treatment. Suc-
cessful gene silencing was analyzed via
Western blotting and is depicted in the
inset. n3. B, Cells were pretreated for
30 minutes with the c-Jun N-terminal
kinase inhibitor SP600125 (SP). n3. C,
Cells were pretreated for 30 minutes
with the CK2 inhibitors 4,5,6,7-tetrabromo-
2-azabenzimidazole (TBB) or quinalizarin
(Q). n3. D, Cells were pretreated for 30
minutes with a myristoyated PKC
pseudosubstrate inhibitor. n3.
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nmol/L.20 In good accordance with these findings, we could
detect neither a cytotoxic action nor a cellular protein
content–lowering effect (data not shown) of flavopiridol at
100 nmol/L in ECs. Thus, we can exclude detrimental effects
on global transcription.
It has been a matter of debate whether CDK9 governs gene
transcription in general or regulates restricted sets of genes.
Recently, a selective modulation of gene expression by
CDK9 has been reported, because CDK9 inhibition induced
not only a downregulation but also an (even more pro-
nounced) upregulation of genes.21 Moreover, CDK9/P-TEFb
has been discovered to play an important role in TNF--
induced NF-B activation by forming a protein complex with
activated p65 in the nucleus. However, P-TEFb regulates
only a subset of NF-B-dependent genes. The P-TEFb-p65
complex is required for IL-8 and Gro- but not for IB-
gene activation.22,23 Our data prompted us to suggest that
P-TEFb-p65 interaction might also be in charge of ICAM-1
gene transcription. The inhibition of CDK9/P-TEFb by fla-
vopiridol effortlessly explains the reduction of NF-B-
dependent gene expression in the absence of any effect on the
canonical upstream NF-B activation cascade: flavopiridol
blocks gene expression controlled by NF-B at a very late
stage, ie, after transcription has been initiated.
Our work highlights inhibition of CDK9 as an interesting
approach against inflammation-associated pathologies. On
the basis of a few studies, CDK9 inhibition was thought to be
of potential value to fight inflammation. Independent of its
function as a subunit of P-TEFb, CDK9 was found to interact
with cytoplasmic regions of gp130,24 the receptor for the
proinflammatory cytokine IL-6. An additional study reported
that CDK9 inhibitors disrupt the IL-6/STAT3 signaling in the
liver.14 HEXIM1, an endogenous inhibitor of P-TEFb, was
shown to associate with NF-B p65 and to repress NF-B-
dependent gene transcription in smooth muscle cells.25 How-
ever, to the best of our knowledge, this is the first study
scrutinizing the action of CDK9 inhibition on leukocyte-EC
interaction and, in particular, on endothelial activation, a
crucial inflammation-triggering event.
In summary, our study provides evidence that low-dose
flavopiridol effectively protects against inflammation-induced
interactions between leukocytes and the endothelium, primar-
B
A
CDK8
β-actin
100
120 nt siRNA
CDK8 siRNA
-
+
+
-100
IC
A
M
-1
 s
ur
fa
ce
ex
pr
es
si
on
(%
)
20
40
60
80
TN
F-
in
du
ce
d
IC
A
M
-1
 
ur
fa
ce
ex
pr
es
si
on
(%
)
50
100
150
200
fascaplysin (nM)
+ TNF
Co TNF 30 100 300 1000
0 0
T su
nt siRNA
CDK8 siRNA
-
+
+
-
C Cdk9
β-tubulin
C
A
M
-1
io
n
(%
)
80
100
nt shRNA
CDK9 shRNA
-
+
+
-
120
C
A
M
-1
si
on
(%
)
80
100
120
D Cdk9
β-tubulin
nt shRNA
CDK9 shRNA
-
+
+
-
nt shRNA
CDK9 hRNA
-+
0
TN
F-
in
du
ce
d
IC
su
rfa
ce
ex
pr
es
si
20
40
60
*
0
TN
F-
in
du
ce
d
V
su
rfa
ce
ex
pr
es
s
20
40
60
nt shRNA
CDK9 shRNA
-
+
+
*
 s+- -
ec
tin
n
(%
)
100
120
E
0
TN
F-
in
du
ce
d
E
-s
el
su
rfa
ce
ex
pr
es
si
on
20
40
60
80
nt shRNA-+
*
CDK9 shRNA+-
Figure 6. Inhibition of CDK9 but not of
CDK4, CDK6, and CDK8 is responsible
for the action of flavopiridol on ICAM-1
expression. A to E, HUVECs were either
left untreated (Co) or treated with TNF-
(10 ng/mL) for 24 hours (ICAM-1,
VCAM-1) or 6 hours (E-selectin). Adhe-
sion molecule surface expression were
assessed by flow cytometry. A, Cells
were pretreated for 30 minutes with the
CDK4/6 inhibitor fascaplysin. n3. B,
Cells were transfected with CDK8 siRNA
or nontargeting (nt) siRNA 24 hours
before TNF- treatment. Successful
gene silencing was confirmed by West-
ern blotting and is depicted in the inset.
n3. C to E, Cells were transfected with
CDK9 shRNA or nt shRNA 72 hours
before TNF- treatment. Successful
gene silencing was confirmed by West-
ern blotting and is depicted in the inset.
n3. *P0.05 versus TNF-  nt
shRNA.
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ily by blocking endothelial activation. This is achieved by an
inhibition of the proinflammatory transcription factor NF-B.
Most importantly, the canonical NF-B activation cascade is
not altered by flavopiridol, whereas NF-B-induced tran-
scription is decreased via inhibition of CDK9. Thus, our work
highlights flavopiridol as a promising antiinflammatory agent
and, moreover, discloses inhibition of CDK9 as an interesting
approach for the treatment of inflammation-associated
diseases.
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